CB2 Insights Licenses Electronic Data Capture Software to MyAccess Clinics for Use In the UK
  • Company strengthens market presence in United Kingdom with licensing of Electronic Data Capture Technology in partnership with UK-based MyAccess Clinics
  • MyAccess Clinics to use CB2’s software within multi-clinic operation in the UK for data input and management
  • Software will allow MyAccess Clinics to capture comprehensive data sets related to patient health and treatment histories and manage ongoing medical cannabis treatment outcome data
  • In July, CB2 Insights announced its partnership to serve as exclusive research technology platform for a 20,000 patient medical cannabis pilot in the UK, led by Drug Science

TORONTO, ON – September 19, 2019  CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that MyAccess Clinics (“MAC”) has selected CB2 Insights’ Electronic Data Capture (EDC) software to manage patient data within its growing number of medical clinics in the UK. MyAccess Clinics is a wholly-owned subsidiary of leading global medical cannabis company, Althea Group Holdings Ltd (ASX:AGH).

“The UK market continues to blossom at a rapid pace, and we are proud that our research and data technology assets continue to be sought to expedite growth in the market,” said Prad Sekar, Chief Executive Officer, CB2 Insights.  “MyAccess Clinics has an exceptional and comprehensive vision for its development in the UK’s medical cannabis market and we are excited to be a part of that effort.”

CB2 Insights’ EDC software has been used throughout the US and Canada and uses standard healthcare protocols. The system is purpose-built for medical cannabis operations and takes into account the complexity of managing data related to multiple indications across a single patient base, comorbidity in certain patient profiles, past traditional therapies and multiple consumption methods and medicine within a single treatment plan.  The system works to simplify data input and management while ensuring collection can ultimately be used to better understand the efficacy of cannabinoid therapy.  This deployment will increase both the size and scope of the Company’s data set.

Graham Woodward, MyAccess Clinics Clinical Director said “As a company, we are proud to be one of the first to service the emerging UK medical cannabis market. CB2 Insights’ software will play an integral part in  the administration of our clinics and will increase our ability to manage data, thereby improving our patient care.”

Earlier this year, CB2 Insights announced that it had been selected as the exclusive research technology platform for UK-based Drug Science and its medical cannabis pilot program.

Skylight Health

Author Skylight Health

More posts by Skylight Health

Leave a Reply